LB Pharmaceuticals Inc
LBRX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001691082
No open-market purchases or sales by LB Pharmaceuticals Inc insiders were filed in the last 90 days; 114 institutions reported holding it in 13F filings for Q2 2026, worth $1.00B in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +39 vs. previous quarter
- 114
- 13F valueReported value at the end of Q2 2026
- $1.00B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding LBRX, Q2 2026
No superinvestor reported holding LBRX at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by LB Pharmaceuticals Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 3, 2026 (view filing)7:28 PM ET | Jul 30 | 4 days | Kroin David and 2 others10% Owner | PPurchase | +286.2K | $34.94 | +$10.0M | –664.6K after | Derivative |
| Feb 10, 2026 (view filing)4:30 PM ET | Feb 6 | 4 days | Kroin David and 3 others10% Owner | PPurchase | +378.4K | $21.17 | +$8.01M | –378.4K after | Derivative |
| Feb 10, 2026 (view filing)4:30 PM ET | Feb 6 | 4 days | Kroin David and 3 others10% Owner | PPurchase | +93.9K | $21.17 | +$1.99M | –93.9K after | Derivative |
| Sep 16, 2025 (view filing)6:09 PM ET | Sep 12 | 4 days | Kroin David and 2 others10% Owner | PPurchase | +2.00M | $15.00 | +$30.0M | +291.5%2.69M after | |
| Sep 16, 2025 (view filing)6:09 PM ET | Sep 12 | 4 days | Kroin David and 2 others10% Owner | PPurchase | +666.7K | $15.00 | +$10.0M | New position666.7K after | |
| Sep 16, 2025 (view filing)3:46 PM ET | Sep 12 | 4 days | Belldegrun Arie and 4 others10% Owner | PPurchase | +333.3K | $15.00 | +$5.00M | New position2.03K after | 2 lots |
| Sep 16, 2025 (view filing) | Sep 12 | 4 days | Pontifax Management 4 G.P. (2015) Ltd.10% Owner | PPurchase | +1.00M | $15.00 | +$15.0M | +242.9%1.41M after | Duplicate filing |
| Sep 16, 2025 (view filing) | Sep 12 | 4 days | Nussbaum RanDirector | PPurchase | +1.00M | $15.00 | +$15.0M | +242.9%1.41M after |
Top 10 13F holders, Q2 2026
The largest institutional positions in LB Pharmaceuticals Inc at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Deep Track Capital, LP | 3,352,804 | $108.8M | 1.60% | 00.0% | Unchanged |
| BlackRock, Inc. | 2,734,305 | $88.7M | 0.00% | +263,460+10.7% | Added |
| Ra Capital Management, L.P. | 2,208,604 | $71.7M | 0.62% | 00.0% | Unchanged |
| Nantahala Capital Management, LLC | 2,105,788 | $68.3M | 2.07% | +1,052,894+100.0% | Added |
| Trails Edge Capital Partners, LP | 1,523,022 | $49.4M | 7.85% | +203,660+15.4% | Added |
| JPMorgan Chase & Co | 1,497,293 | $48.9M | 0.00% | +69,725+4.9% | Added |
| Commodore Capital LP | 1,500,000 | $48.7M | 2.90% | 00.0% | Unchanged |
| TCG Crossover Management, LLC | 1,447,310 | $47.0M | 1.13% | −392,179−21.3% | Reduced |
| Caligan Partners LP | 1,438,070 | $46.7M | 2.25% | 00.0% | Unchanged |
| Spruce Street Capital LP | 1,376,159 | $44.7M | 8.76% | 00.0% | Unchanged |